GGrantIndex
← Leaderboards

Craig A Henke

University Of Minnesota Twin Cities

$12,056,250
Attributed
$12,638,195
Total exposure
10
Grants
8
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $2.7M · FY200522
$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22

Funding mix

By agency

NIH$20,961,215 · 11

By mechanism

P01$11,272,028 · 3
R01$7,764,887 · 5
P50$760,410 · 1
R25$748,640 · 1
R21$415,250 · 1

Top collaborators

Most similar at University Of Minnesota Twin Cities

Same institution · by research overlap

Others in their field

Top investigators on “Fibroblasts

Research focus

FibroblastsRegulationPhenotypeBaseCollagenLung DiseasesSignal TransductionDepositionCellsIntegrinsMemberStructure Of Parenchyma Of LungLungSignal PathwayAlveolarFibrosisPathologicMyofibroblastMolecularTissuesIn VivoPathway InteractionsResponseHamman-Rich Syndrome

Grant awards (46)

S100A4 Regulation of IPF Mesenchymal Progenitor Cell Fibrogenicity$522,986
R01 · FY2022 · HL · contact PI
S100A4 Regulation of IPF Mesenchymal Progenitor Cell Fibrogenicity$592,286
R01 · FY2021 · HL · contact PI
Summer Research at the University of Minnesota Medical School$186,620
R25 · FY2021 · HL
S100A4 Regulation of IPF Mesenchymal Progenitor Cell Fibrogenicity$601,271
R01 · FY2020 · HL · contact PI
Summer Research at the University of Minnesota Medical School$188,780
R25 · FY2020 · HL
S100A4 Regulation of IPF Mesenchymal Progenitor Cell Fibrogenicity$604,351
R01 · FY2019 · HL · contact PI
Summer Research at the University of Minnesota Medical School$186,620
R25 · FY2019 · HL
Integrin-Matrix Regulation of IPF Fibroblast Phenotype$419,999
R01 · FY2018 · HL · contact PI
Summer Research at the University of Minnesota Medical School$186,620
R25 · FY2018 · HL
Integrin-Matrix Regulation of IPF Fibroblast Phenotype$450,903
R01 · FY2017 · HL · contact PI
Integrin-Matrix Regulation of IPF Fibroblast Phenotype$458,503
R01 · FY2016 · HL · contact PI
Integrin-Matrix Regulation of IPF Fibroblast Phenotype$514,134
R01 · FY2015 · HL · contact PI
IPF Fibroblast Phenotype$1,592,769
P01 · FY2013 · HL · contact PI
Integrin-ECM regulation of fibroblast proliferation$393,832
P01 · FY2013 · HL · contact PI
Integrin-collagen signaling and control of fibroblast proliferation$154,289
R01 · FY2013 · HL · contact PI
Administrative Core$120,664
P01 · FY2013 · HL · contact PI
IPF Fibroblast Phenotype$1,673,077
P01 · FY2012 · HL · contact PI
Integrin-ECM regulation of fibroblast proliferation$413,687
P01 · FY2012 · HL · contact PI
Integrin-collagen signaling and control of fibroblast proliferation$162,068
R01 · FY2012 · HL · contact PI
Administrative Core$126,750
P01 · FY2012 · HL · contact PI
IPF Fibroblast Phenotype$1,673,077
P01 · FY2011 · HL · contact PI
Integrin-ECM regulation of fibroblast proliferation$413,685
P01 · FY2011 · HL · contact PI
Integrin-collagen signaling and control of fibroblast proliferation$163,705
R01 · FY2011 · HL · contact PI
Administrative Core$126,751
P01 · FY2011 · HL · contact PI
IPF Fibroblast Phenotype$1,673,490
P01 · FY2010 · HL · contact PI
Administrative Core$334,698
P01 · FY2010 · HL · contact PI
Integrin-ECM regulation of fibroblast proliferation$334,698
P01 · FY2010 · HL · contact PI
Role of Fox03a in Regulating the IPF Fibroblast Phenotype$226,500
R21 · FY2010 · HL · contact PI
Integrin-collagen signaling and control of fibroblast proliferation$163,705
R01 · FY2010 · HL · contact PI
IPF Fibroblast Phenotype$1,710,607
P01 · FY2009 · HL · contact PI
Administrative Core$342,122
P01 · FY2009 · HL · contact PI
Integrin-ECM regulation of fibroblast proliferation$342,121
P01 · FY2009 · HL · contact PI
Role of Fox03a in Regulating the IPF Fibroblast Phenotype$188,750
R21 · FY2009 · HL · contact PI
Integrin-collagen signaling and control of fibroblast proliferation$163,705
R01 · FY2009 · HL · contact PI
Extracellular Matrix Regulation of Fibroblast Viability$323,892
R01 · FY2008 · HL · contact PI
Extracellular Matrix Regulation of Fibroblast Viability$316,941
R01 · FY2007 · HL · contact PI
Extracellular Matrix Regulation of Fibroblast Viability$321,759
R01 · FY2006 · HL · contact PI
Fibroblast Ablation as Treatment for Pulmonary Fibrosis$277,054
R01 · FY2006 · HL · contact PI
Extracellular Matrix Regulation of Fibroblast Viability$326,148
R01 · FY2005 · HL
Fibroblast Ablation as Treatment for Pulmonary Fibrosis$275,923
R01 · FY2005 · HL
Fibroblast Ablation as Treatment for Pulmonary Fibrosis$268,353
R01 · FY2004 · HL
Fibroblast Ablation as Treatment for Pulmonary Fibrosis$279,544
R01 · FY2003 · HL
Fibroblast Ablation as Treatment for Pulmonary Fibrosis$403,368
R01 · FY2002 · HL
MECHANISM OF INDUCTION OF FIBROBLAST APOPTOSIS BY ANTICD44 ANTIBODY$245,455
P50 · FY2002 · HL
MECHANISM OF INDUCTION OF FIBROBLAST APOPTOSIS BY ANTICD44 ANTIBODY$245,455
P50 · FY2001 · HL
MECHANISM OF INDUCTION OF FIBROBLAST APOPTOSIS BY ANTICD44 ANTIBODY$269,500
P50 · FY2000 · HL